The U.S. Food and Drug Administration granted priority review to Dova Pharmaceuticals Inc.'s avatrombopag to treat thrombocytopenia in patients with chronic liver disease who are scheduled to undergo a procedure.
Thrombocytopenia is a condition that causes the blood platelet count to be lower than normal.
The application is based on two phase 3 trials in which the drug met all primary and secondary endpoints with high statistical significance.
The agency is expected to make a decision on the drug by May 21, 2018.
